Ajovy vs Nurtec ODT

At a glance

Key differences

• Same class. Both Ajovy and Nurtec ODT are CGRP inhibitors, so they work through the same broad mechanism. Differences between them tend to be about dosing, route, how selective they are, and side effects rather than what they target.
• How they are taken. Ajovy is given by the subcutaneous route; Nurtec ODT by the oral route.
• Time on the market. Ajovy was first approved by the FDA in 2018, Nurtec ODT in 2020. That gives Ajovy roughly 2 more years of real-world use and long-term safety data.
• Who markets them. Ajovy is marketed by Teva; Nurtec ODT by Pfizer.
• Same drug, more than one brand. Rimegepant is sold as Nurtec ODT / Vydura — the same active ingredient marketed under different brand names, typically for different approved uses or doses.

What each one treats

How each one works

Related comparisons

Read more

Class and summary text is written by the Priya Life Science editorial team. Label, mechanism, route, manufacturer and approval data come from the U.S. FDA via the openFDA API; shortage status from the FDA Drug Shortage Database. Approvals, indications and brand names differ between the US, EU/Ireland (EMA/HPRA) and other regions — a drug approved in one may not be approved, or may carry a different name, in another.